OX40L blockade and allergen-induced airway responses in subjects with mild asthma
Version of Record online: 20 DEC 2013
© 2013 The Authors Clinical & Experimental Allergy Published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Clinical & Experimental Allergy
Volume 44, Issue 1, pages 29–37, January 2014
How to Cite
Clinical & Experimental Allergy, 2014 (44) 29–37., , , , , , , , , , , , , , , , , and .
- Issue online: 20 DEC 2013
- Version of Record online: 20 DEC 2013
- Accepted manuscript online: 14 NOV 2013 12:50AM EST
- Manuscript Accepted: 16 OCT 2013
- Manuscript Revised: 9 SEP 2013
- Manuscript Received: 10 JUN 2013
- Genentech Inc.,
|cea12235-sup-0001-Fig1.pdf||application/PDF||172K||Figure S1. The mean (background subtracted) frequency of antigen-specific IFNγ-secreting T cells before and after treatment with anti-OX40L MAb. PBMC were isolated before (Day 5) and after (Day 112) treatment with placebo or anti-OX40L MAb, and cultured with sensitizing allergen and recall antigen.|
|cea12235-sup-0002-Fig2.pptx||application/pptx||121K||Figure S2. The mean (SEM) number of mDC1 (top panel), mDC2 (middle panel) and pDCs (bottom panel) following treatment with placebo (open bars) and anti-OX40L MAb (solid bars) measured post-treatment Days 55 and 112 (pre-allergen) and 57 and 114 (24 hrs after allergen challenge).|
|cea12235-sup-0003-SuppInfo.docx||Word document||53K||Data S1. Additional methods and results.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.